AMBION DIAGNOSTICS, INC.

Basic Information

Asuragen, Inc.
2150 WOODWARD ST
AUSTIN, TX, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 611733069
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Identification of microRNA Biomarkers for Colon Cancer Recurrence Risk Stratifica

    Amount: $312,292.00

    DESCRIPTION (provided by applicant): The current primary form of treatment for all stages of colon cancer is surgical resection, with overall survival rates depending upon whether the cancer recurs an ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Technologies for mapping interspersed AGG sequences in the FMR1 gene

    Amount: $192,196.00

    DESCRIPTION (provided by applicant): The objective of this project is to develop a comprehensive set of assays to improve screening and prediction of conditions associated with fragile X syndrome (FXS ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Amplification Strategies for Detection of Fragile X Gene Trinucleotide Repeats

    Amount: $1,096,210.00

    DESCRIPTION (provided by applicant): The overall objective for this project is to develop and implement a comprehensive set of technologies to improve screening and diagnosis of conditions associa ...

    SBIR Phase II 2010 Department of Health and Human Services
  4. Single molecule fluorescence detection of fragile X mutations

    Amount: $324,290.00

    DESCRIPTION (provided by applicant): Fragile X Syndrome (FXS), is the most common form of inherited mental retardation, affecting 1 in 4000 males and about 1 in 6000 females of all ethnicities. Addit ...

    STTR Phase I 2009 Department of Health and Human Services
  5. Amplification Strategies for Detection of Fragile X Trinucleotide Repeats

    Amount: $414,193.00

    DESCRIPTION (provided by applicant): The overall objective for this project is to develop and implement a comprehensive set of technologies to improve screening and diagnosis of conditions associated ...

    SBIR Phase I 2009 Department of Health and Human Services
  6. MicroRNA Markers of Melanoma Metastasis in Lymph Nodes

    Amount: $256,920.00

    DESCRIPTION (provided by applicant): Malignant melanoma is the least frequent but the most aggressive and deadliest form of skin cancer. Early detection and accurate staging are therefore crucial to e ...

    SBIR Phase I 2009 Department of Health and Human Services
  7. Identification of microRNA Biomarkers for Lung Cancer

    Amount: $273,456.00

    DESCRIPTION (provided by applicant): In the United States, lung cancer has the highest incidence and the highest mortality rate of all cancers. An estimated 215,020 new cases of lung cancer and an est ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. Multiplex Detection of Mutations in Leukemia Patients

    Amount: $1,192,160.00

    DESCRIPTION (provided by applicant): The long-term objective of this project is to develop a comprehensive molecular diagnostic assay for the detection of clinically relevant genetic abnormalities in ...

    SBIR Phase II 2009 Department of Health and Human Services
  9. RNA Amplification for Diagnostic Microarrays

    Amount: $1,162,790.00

    DESCRIPTION (provided by applicant): The overall goal of this proposal is to develop and implement an integrated suite of technologies for enabling microarray-based diagnostic assays and the cGMP manu ...

    SBIR Phase II 2009 Department of Health and Human Services
  10. Novel RNA Markers for Detecting Colon Cancer Metastasis

    Amount: $277,748.00

    DESCRIPTION (provided by applicant): Lymph node evaluation is an important prognostic factor in colorectal cancer (CRC) because accurate identification of lymph node metastases significantly influence ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government